Avidity Biosciences Completes $100 Million Series C Financing

LA JOLLA, Calif.–(BUSINESS WIRE)–Avidity Biosciences, a biotechnology company pioneering Antibody-Oligonucleotide Conjugates (AOCs?) for the treatment of rare muscle disorders and other serious diseases, announced the completion of a $100 million Series C financing. The financing was led by RTW Investments and included new investors Cormorant Asset Management, LP, CureDuchenne, Logos Capital, Perceptive Advisors LLC and ST Pharm. Existing investors also participated and include Alethea Capita